Abstract
Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.
Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer
Recent Patents on Anti-Cancer Drug Discovery
Title: Molecularly Targeted Therapy in Breast Cancer: The New Generation
Volume: 3 Issue: 2
Author(s): Zeina A. Nahleh
Affiliation:
Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer
Abstract: Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.
Export Options
About this article
Cite this article as:
Nahleh A. Zeina, Molecularly Targeted Therapy in Breast Cancer: The New Generation, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638794
DOI https://dx.doi.org/10.2174/157489208784638794 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic :Current Advances In Therapeutic Applications of Nuclear Receptors (Guest Editor: Stefano Fiorucci)]
Current Topics in Medicinal Chemistry <i>In vivo</i> Evaluation of [<sup>225</sup>Ac]Ac-DOTA<sup>ZOL</sup> for α-Therapy of Bone Metastases
Current Radiopharmaceuticals Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes
Current Medicinal Chemistry Exploring and Exploiting Microbial Diversity through Metagenomics for Natural Product Drug Discovery
Current Topics in Medicinal Chemistry Synthesis of 2,5-Disubstituted-1,3,4-oxadiazole Analogs as Novel Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Editorial Review 2015
Current Radiopharmaceuticals Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice
Current Cancer Drug Targets Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Advanced Cardiac Imaging of Radiation-induced Injury - a Review
Current Medical Imaging High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry Antimicrobial Peptides Present in Mammalian Skin and Gut are Multifunctional Defence Molecules
Current Pharmaceutical Design Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Synthesis and Biological Evaluation of a Novel Apogossypolone Derivative
Letters in Drug Design & Discovery Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA The Tumor Suppressor Role of the Ras Association Domain Family 10
Anti-Cancer Agents in Medicinal Chemistry Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Editorial (Thematic Issue: Application of Novel Computational Methods in Molecular Biology, Biomedicine and Biopharmacy)
Current Bioinformatics Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery